Gujarat Kidney Secures Rs 100 Cr Pre-IPO From Anchor Investors; GMP Rises To 6.14% Ahead of IPO Opening
Ipo
Prior to its IPO, which will begin accepting public subscriptions on December 22, Gujarat Kidney and Super Speciality has raised Rs 100 crore from anchor investors. The company notified the stock exchanges that it issued anchor investors 87,73,120 equity shares at a price of Rs 114 each.
Venus Investments VCC – Venus Stellar Fund, Khandelwal Finance Private Limited, Craft Emerging Market Fund PCC Citadel Capital Fund, Nexus Global Opportunities Fund, Arnesta Global Opportunities Fund PCC – Arnesta Global Fund 1, Zeta Global Funds – Zeta Series C Fund PC, Innovative Vision Fund, Religo Commodities Ventures Trust, and Sunrise Investment Trust are a few of the prominent institutions that took part in the anchor in the pre-IPO round.
Gujarat Kidney IPO is a book build issue of Rs 250.80 crores, comprising a fresh issue of 2.20 crore shares of Rs 250.80 crores. For its initial IPO, Gujarat Kidney and Super Speciality Ltd. has set a price band of Rs 108 to Rs 114 per equity share with a face value of Rs 2. Investors can bid for a minimum of 128 equity shares and in multiples of 128 equity shares thereafter.
Subscriptions for the Gujarat Kidney IPO will commence on December 22, 2025, and finish on December 24, 2025. On December 26, 2025, the share allotment for the Gujarat Kidney IPO is anticipated to be completed. The Gujarat Kidney IPO is scheduled to list on the BSE and NSE on December 30, 2025.
For the year that ended on March 31, 2025, the company’s revenue from operations was Rs 40.24 crore, and its net profit was Rs 9.49 crore. During the three months that ended on June 30, 2025, the company’s revenue from operations was Rs 15.26 crore, and its net profit was Rs 5.40 crore.
The offer is being made through the book-building procedure, with qualified institutional buyers receiving no more than 75% of the net offer and non-institutional bids and retail individual bidders receiving no more than 15% and 10% of the net offer, respectively. The offer’s registrar is MUFG Intime India Limited, and the book-running lead manager is Nirbhay Capital Services Private Limited.
With its most recent grey market premium (GMP) of Rs 7 as of December 20, 2025, updated at 04:35 PM, Gujarat Kidney IPO is exhibiting a somewhat positive attitude in the unlisted market. The expected listing price, taking into account the current GMP, comes to about Rs 121 based on the upper end of the IPO price band at Rs 114 per share. This corresponds to an anticipated listing gain of around 6.14% per share, suggesting cautious optimism among investors prior to the stock’s debut.
Located in Gujarat’s central region, the organization is a regional healthcare provider that runs a network of mid-sized, multispecialty hospitals that offer integrated healthcare services with an emphasis on secondary and tertiary care. Gujarat Kidney and Super Speciality Limited has filed a red herring prospectus dated December 12, 2025, and has decided to launch an initial public offering.